Warburg Pincus has just filed a Form 13D with the SEC, updating the regulatory body on the latest pertinent information related to its position in China Biologic Products Inc (NASDAQ:CBPO). The activist filing reveals that the investment firm has sold over half of its stake in the company since the end of 2015, when it held 8.34 million shares. The firm now owns 4.09 million shares of the issuer.
Item 4 of the filing was updated with the following information related to the recent large sale of shares:
“On March 4, 2016, the Underwriter notified the Funds of its election to exercise the option to purchase additional Shares from the Funds in full.
On March 7, 2016, the Funds sold an aggregate of 4,257,000 Shares to the Underwriter at a price of $107.00 per Share pursuant to the Underwriting Agreement.”
Shares of CBPO currently trade at $109.28 and are down by 23% this year.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|WP X Biologics||0||3,112,920||0||3,112,920||3,112,920||11.7%|
|Warburg Pincus Private Equity X||0||3,960,496||0||3,960,496||3,960,496||14.9%|
|Warburg Pincus X Partners||0||126,704||0||126,704||126,704||0.5%|
|Warburg Pincus X||0||4,087,200||0||4,087,200||4,087,200||15.4%|
|Warburg Pincus X GP||0||4,087,200||0||4,087,200||4,087,200||15.4%|
|Warburg Pincus Partners||0||4,087,200||0||4,087,200||4,087,200||15.4%|
|Warburg Pincus Partners GP||0||4,087,200||0||4,087,200||4,087,200||15.4%|
|Warburg Pincus Co||0||4,087,200||0||4,087,200||4,087,200||15.4%|
|Charles R. Kaye||0||4,087,200||0||4,087,200||4,087,200||15.4%|
|Joseph P. Landy||0||4,087,200||0||4,087,200||4,087,200||15.4%|
Page 1 of 17 SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. 15)*
Biologic Products, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
Robert B. Knauss
Managing Director and General Counsel
Warburg Pincus LLC
New York, NY 10017
With a copy to:
Weiheng Chen, Esq.
Wilson Sonsini Goodrich & Rosati, P.C.
Suite 1509, 15/F, Jardine House
1 Connaught Place, Central
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
March 7, 2016
Event Which Requires Filing of This Statement)
If the filing
person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following